PR Newswire Clinical TrialsOriginal article
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Phase 3CardiolRxPositive
AI Analysis
Summary
Cardiol Therapeutics achieved its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule and expanded the trial to up to 150 patients to strengthen efficacy assessment of CardiolRx in reducing recurrence risk.
Clinical Trial Data
Phase
Phase III
Patients
150
Outcome Details
Enrollment target of 110 patients achieved ahead of schedule; trial expanded to up to 150 patients
Importance:6/10
Sentiment:
0.70
Phase 3enrollmentMAVERIC trialcardiactrial expansion
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 23, 2026 10:00 AM